citalopram has been researched along with Nervous System Disorders in 6 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients who had had an acute stroke within the past 21 days were randomly assigned in a 1:1 ratio to receive oral escitalopram (10 mg/day) or placebo for 3 months." | 9.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 5.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| " Patients who had had an acute stroke within the past 21 days were randomly assigned in a 1:1 ratio to receive oral escitalopram (10 mg/day) or placebo for 3 months." | 5.24 | Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. ( Ahn, SH; Cha, JK; Chang, DI; Choi-Kwon, S; Heo, JH; Kim, DE; Kim, HY; Kim, J; Kim, JS; Kim, JY; Kim, S; Koh, SH; Kwon, DY; Lee, BC; Lee, EJ; Lee, J; Park, JH; Park, SW; Seo, WK; Sohn, SI, 2017) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 1.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, N | 1 |
| Qin, W | 1 |
| Tian, S | 1 |
| Xu, Q | 1 |
| Wold, EA | 1 |
| Zhou, J | 1 |
| Zhen, XC | 1 |
| Chen, S | 1 |
| Bennet, L | 1 |
| McGregor, AL | 1 |
| Kim, JS | 1 |
| Lee, EJ | 1 |
| Chang, DI | 1 |
| Park, JH | 1 |
| Ahn, SH | 1 |
| Cha, JK | 1 |
| Heo, JH | 1 |
| Sohn, SI | 1 |
| Lee, BC | 1 |
| Kim, DE | 1 |
| Kim, HY | 1 |
| Kim, S | 1 |
| Kwon, DY | 1 |
| Kim, J | 1 |
| Seo, WK | 1 |
| Lee, J | 1 |
| Park, SW | 1 |
| Koh, SH | 1 |
| Kim, JY | 1 |
| Choi-Kwon, S | 1 |
| Procaccini, C | 1 |
| Aitta-aho, T | 1 |
| Jaako-Movits, K | 1 |
| Zharkovsky, A | 1 |
| Panhelainen, A | 1 |
| Sprengel, R | 1 |
| Linden, AM | 1 |
| Korpi, ER | 1 |
| Mead, GE | 1 |
| Hsieh, CF | 1 |
| Lee, R | 1 |
| Kutlubaev, MA | 1 |
| Claxton, A | 1 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Tietz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement[NCT01278498] | Phase 4 | 444 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for citalopram and Nervous System Disorders
| Article | Year |
|---|---|
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
Topics: Allosteric Regulation; Clinical Trials as Topic; Humans; Ligands; Nervous System Diseases; Piperidin | 2020 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
1 trial available for citalopram and Nervous System Disorders
3 other studies available for citalopram and Nervous System Disorders
| Article | Year |
|---|---|
Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice.
Topics: Animals; Brain Ischemia; Citalopram; Disease Models, Animal; Encephalitis; Ischemic Stroke; Mice; Ne | 2022 |
Excessive novelty-induced c-Fos expression and altered neurogenesis in the hippocampus of GluA1 knockout mice.
Topics: Animals; Behavior, Animal; Citalopram; Exploratory Behavior; Female; Genotype; Hippocampus; Male; Mi | 2011 |
[Stage CDC C3 HIV infection; V.a. acute serotoninergic syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Citalopram; Diagnosis, Differential; Drug Therapy, Com | 1997 |